AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...
The company laid out its restructuring plans in a regulatory document. These include a workforce reduction of around 20%. Before market open, Recursion disclosed in a tersely worded regulatory filing ...
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results